Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Circe Biosciences

Explore full profile

Developing a manufacturing platform capable of producing any organic molecule using carbon dioxide, water, and electricity

Boston, United StatesFounded 2021Energy
Valuation $25–50M Last recorded · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Circe Biosciences and the history behind them.

About Circe Biosciences

Circe Biosciences, Inc. operates at the intersection of synthetic biology and decarbonization, developing a manufacturing platform that transforms carbon dioxide into a variety of valuable chemicals. The company was co-founded by Shannon Nangle and Marika Ziesack, who both bring extensive experience from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their collective background in gas fermentation and synthetic biology underpins the company's core technology. The process leverages gas fermentation, utilizing microbes that consume greenhouse gases like carbon dioxide, along with water and electricity, to produce a range of organic molecules.

The primary goal is to provide a sustainable alternative to traditional petrochemical-based manufacturing, thereby reducing the carbon footprint of numerous industries. Circe Biosciences' platform is designed to create products such as triglycerides for food production, bioplastics, and other specialty chemicals. This approach targets industries reliant on these materials, offering them a method to decarbonize their supply chains. The business model appears to be centered on producing and selling these sustainably sourced molecules or potentially licensing the technology to large-scale manufacturing partners. By converting a waste product (CO2) into essential goods, the company aims to build a more resilient and circular economy.

The company's platform functions by engineering microbes to be highly efficient at converting CO2 into specific target molecules. This fermentation process is positioned as a direct competitor to conventional methods that rely on fossil fuels. Significant milestones include securing a $1 million investment from The Engine, a venture firm with roots at MIT, which has provided crucial early-stage support. The company has also been recognized through various awards, including participation in the 2022 cohort of the Third Derivative accelerator program, underscoring its potential impact on climate technology. This technology offers the benefit of producing familiar products through a fundamentally different and more environmentally friendly pathway.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
Boston, United States
Employees
51
Open positions
None listed
Dealroom signal
61.6/100
Sub-industry
Clean Energy, Innovative Food
Sector
Energy, Biotechnology, Spinout, Sustainable Development Goals, Fermentation, Biotechnology in Food, Climate Tech, Alternative Fats and Oils, DT and LS
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
b2b

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Sep 2024 $5M $40M Bee Partners · Ponderosa Ventures · ReGen Ventures · Safar Partners —
EARLY VC✓Equity / VC May 2024 $8M $32M Bee Partners · Undeterred Capital · ReGen Ventures · Elementum Ventures ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Circe Biosciences website traffic

Latest recorded traffic for Circe Biosciences is 410 monthly website visits, down 48.1% over the last three months. Circe Biosciences's team grew 0% over the past year.

Latest monthly visits410 3-month web change-48.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • ARPA-E
  • Safar Partners
  • Exceptional Ventures
  • Climate Capital

Series A5 investors entered at this stage

  • Bee Partners
  • Undeterred Capital
  • ReGen Ventures
  • Elementum Ventures
  • Ponderosa Ventures

Other known investors4 additional known investors

  • Activate
  • Harvard University
  • Wyss Institute
  • Juniper
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States85.7%
🇦🇺 Australia14.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Circe Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Circe Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.